Neuberger Berman Group
INDV icon

Neuberger Berman Group’s Indivior Pharmaceuticals INDV Stock Holding History

Neuberger Berman Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Buy
7,076
+408
+6% +$14.8K ﹤0.01% 2018
2026
Q1 		$203K Buy
+6,668
New +$220K ﹤0.01% 2001

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group's INDV Position: Q2 2026 in Review

Neuberger Berman Group increased its Indivior Pharmaceuticals (INDV) stake by 6.1% in Q2 2026, buying an estimated $14.8K and bringing the position to 7,076 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #2018.

Neuberger Berman Group first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Neuberger Berman Group held 7,076 shares of Indivior Pharmaceuticals worth $290K as of Q2 2026.
  • Neuberger Berman Group bought 408 Indivior Pharmaceuticals shares in Q2 2026, an estimated $14.8K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2018 holding.
  • Neuberger Berman Group first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.